Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sense Proteomic said that it has expanded its biomarker IP portfolio through filing a patent covering a novel panel of biomarkers for the early diagnosis of systemic lupus erythematosus.
Subscribe to our email newsletter
The Lupus biomarker panel has been developed using Sense Proteomic’s proprietary protein array technology that permits rapid identification of autoantibody biomarkers for cancer and autoimmune diseases, the company said.
Rachel Fallon, joint CEO, said: “We expect this biomarker panel to make a real difference in disease outcome for patients. In addition to facilitating the development of new drug treatments for Lupus, it should greatly improve the early diagnosis of the disease and lead to better control and management of systemic lupus erythematosus (SLE) through improved patient monitoring both within clinical practice and within clinical trials.”